Effects of Immersive Virtual Reality Exercise on Quality of Life, Cognitive Function, and Psychological Symptoms in Individuals With Fibromyalgia
VIR-FM
2 other identifiers
interventional
30
1 country
1
Brief Summary
Fibromyalgia is considered a condition of unknown etiology, affecting approximately 2-5% of the population in developed countries, predominantly women, and is most commonly diagnosed between the ages of 40 and 50. Its main characteristic is the presence of widespread musculoskeletal pain. Although the most frequently reported symptoms include multiple tender points, fatigue, and cognitive dysfunction, this syndrome is also commonly associated with anxiety, depression, and pain catastrophizing. In Chile, fibromyalgia accounts for up to 26.7% of private rheumatology consultations, with a similar scenario observed in the city of Concepción. This highlights the need to implement innovative therapeutic strategies that allow patients to practice motor and cognitive skills in various contexts, including occupational and domestic environments. In this regard, virtual reality has emerged as a promising tool for this population, as it provides a controlled virtual environment where patients can engage in different therapeutic techniques, moving beyond conventional treatment approaches. Through this approach, interventions may include relaxation exercises, cognitive-behavioral therapy, and adapted physical activities. Such interaction may improve cognitive function, reduce symptoms of anxiety, decrease pain perception associated with the condition, and enhance overall quality of life. This study aims to evaluate the effectiveness of a physiotherapy intervention combined with immersive virtual reality on quality of life, cognitive function, and psychological symptoms in patients diagnosed with fibromyalgia. This study corresponds to a randomized controlled crossover clinical trial in which participants will be randomly assigned to one of two groups: Group A will initiate the intervention with physical exercise using immersive virtual reality, while Group B will begin with physical exercise without virtual reality support (control condition). After completing the first intervention period, a crossover will be performed, such that Group A will continue with exercise without virtual reality and Group B will receive the immersive virtual reality intervention. In this way, all participants will experience both exercise modalities, allowing for both within- and between-subject comparisons. A washout period will be included between phases to minimize potential carryover effects. Each group will consist of 21 participants recruited from the Kinesiology Center of Universidad San Sebastián. Cognitive function will be assessed using the Montreal Cognitive Assessment (MoCA), psychological variables will be evaluated using the Depression Anxiety Stress Scales (DASS-21), and quality of life will be measured using the Fibromyalgia Impact Questionnaire-Revised (FIQ-R). All outcomes will be assessed at baseline and after each intervention phase.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2025
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 16, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 26, 2026
CompletedFirst Submitted
Initial submission to the registry
May 13, 2026
CompletedFirst Posted
Study publicly available on registry
May 22, 2026
CompletedMay 22, 2026
May 1, 2026
2 months
May 13, 2026
May 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Quality of life
Quality of life in patients with fibromyalgia will be assessed using the Fibromyalgia Impact Questionnaire-Revised (FIQ-R), which evaluates the impact of fibromyalgia across three dimensions: difficulty in activities of daily living during the past week, overall impact of the disease during the past week, and symptom intensity during the past week. The total score ranges from 0 to 100, with higher values indicating greater symptom severity and a higher level of functional disability
At the beginning and end of the 6-week treatment period
Cognitive function
Cognitive function in both groups will be assessed using the MoCA questionnaire, a brief cognitive assessment tool that measures performance in domains such as memory, orientation, language, attention, executive function, and visuospatial abilities. The MoCA total score ranges from 0 to 30 points, with higher scores indicating better cognitive performance. A score of 26 or higher is generally considered within the normal cognitive range, although cutoff values may vary depending on age, education level, and clinical context.
At the beginning and end of the 6-week treatment period
Psychoemotional variables
Psychoemotional variables will be assessed using the DASS-21 questionnaire, which consists of 21 items designed to evaluate the presence of stress, anxiety, and/or depression. The instrument is divided into three subscales assessing depression, anxiety, and stress, with seven items assigned to each domain. Each item is rated on a 4-point Likert scale ranging from 0 ("did not apply to me at all") to 3 ("applied to me very much or most of the time"). Higher scores indicate greater severity of psychoemotional symptoms.
At the beginning and end of the 6-week treatment period
Sleep quality
Sleep quality was assessed using the Jenkins Sleep Questionnaire, a validated instrument designed to measure the frequency of sleep-related difficulties during the previous week, including problems falling asleep, nighttime awakenings, non-restorative sleep, and fatigue upon waking. The questionnaire consists of four items rated according to the frequency of symptoms experienced, with higher scores indicating poorer sleep quality and greater sleep disturbance.
At the beginning and end of the 6-week treatment period
Secondary Outcomes (2)
User experience
At the beginning and end of the 6-week treatment period
Adherence to the intervention program
At the beginning and end of the 6-week treatment period
Study Arms (2)
Immersive VR → Conventional Exercise
EXPERIMENTALParticipants receive immersive virtual reality exercise followed by conventional exercise.
Conventional Exercise → Immersive VR
ACTIVE COMPARATORParticipants receive conventional exercise followed by immersive virtual reality exercise.
Interventions
Participants will perform a structured physiotherapy program consisting of moderate-intensity aerobic exercise, coordination training, and relaxation techniques, delivered using immersive virtual reality systems (Meta Oculus Quest). Each session will last approximately 60 minutes and will be conducted twice per week for 6 weeks. The program includes 10 minutes of aerobic exercise (cycle ergometer), followed by immersive virtual reality activities comprising 5 minutes of warm-up, 10 minutes of coordination exercises, and 5 minutes of cool-down, concluding with stretching and breathing exercises. Exercise intensity will be monitored using the modified Borg scale. The virtual reality environment is designed to promote motor and cognitive engagement within an interactive setting.
Participants will perform the same structured physiotherapy program consisting of moderate-intensity aerobic exercise, coordination training, and relaxation techniques without the use of immersive virtual reality. Each session will last approximately 60 minutes and will be conducted twice per week for 6 weeks. The program includes 10 minutes of aerobic exercise (cycle ergometer), followed by therapist-guided exercises including 5 minutes of warm-up, 10 minutes of coordination exercises, and 5 minutes of cool-down, concluding with stretching and breathing exercises. Exercise intensity will be monitored using the modified Borg scale.
Eligibility Criteria
You may qualify if:
- Adults aged 18 years or older
- Medical diagnosis of fibromyalgia according to the American College of Rheumatology (ACR) criteria
- Ability to understand and follow study instructions
- Willingness to participate and provide written informed consent
You may not qualify if:
- Pregnancy or breastfeeding
- Oncological pain
- Uncontrolled metabolic disorders
- History of vertigo or conditions that may be exacerbated by virtual reality use
- Any neurological or musculoskeletal condition that limits participation in exercise
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universidad San Sebastián
Concepción, Biobio, 41000, Chile
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Researcher in Musculoskeletal Rehabilitation
Study Record Dates
First Submitted
May 13, 2026
First Posted
May 22, 2026
Study Start
December 15, 2025
Primary Completion
February 16, 2026
Study Completion
February 26, 2026
Last Updated
May 22, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared due to ethical and confidentiality considerations. The study involves sensitive clinical information from patients with fibromyalgia, and data will be handled in accordance with institutional ethical guidelines and data protection regulations. Access to the dataset will be restricted to the research team, and all data will be stored securely in password-protected systems. No identifiable information will be disclosed to external researchers.